HC News

• EMA approval for new drug to treat Alzheimer’s disease
• El papel del radiofísico hospitalario
• Katia Vandekerckhove, dietista- nutricionista especializada en SIBO, microbiota y metagenómica
• A clear and stable vision with cataract surgery at HC Marbella
• Ageing is a luxury, let’s not forget it
• Vårdgarantier för våra nordiska patienter
• Tomas Arrazola. Farmacéutico hospitalario superespecializado en oncología
• Advances and challenges in the fight against cancer
• HC Marbella recibe la certificación ISO 9001:2015, reafirmando su compromiso con la calidad y seguridad asistencial
• Alcohol consumption among adolescents
• More news

HC Marbella, towards improving the management of cancer patients

Spain advances towards the oncological specialization of Hospital Pharmacy, promoting the professional development of hospital pharmacists and improving the management of cancer patients.

Our Hospice Pharmacist, Tomás Arrazola, is today one of the Spanish pharmacists with the most prestigious worldwide certification in oncology pharmacy.

The Board Certified Oncology Pharmacist (BCOP) certification, accredited by the Board of Pharmaceutical Specialties (BPS), accredits the necessary training to ensure compliance with the highest quality standards in the use of cancer medication because of its high toxicity and complexity. Thus, the pharmacist, accredited for integration and collaboration with the Oncology Unit of HC Marbella, helps to plan and optimize treatments adjust doses, prevent medication errors and treat side effects that may result from the treatment.

The BCOP program

The BCOP program is a credential for pharmacists who have met strict eligibility criteria and in their daily practice involves an increasing complexity of pharmacological therapies to treat and prevent cancer. The purpose is to validate that the pharmacist has the advanced knowledge and experience to optimize the results for patients with malignant diseases.

At HC Marbella International Hospital the figure of the cancer pharmacist is fully integrated in the onco-hematology service: actively participating in therapeutic decisions, protocol design and participating in clinical sessions.

July 6, 2019